ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1592957
Pharmacovigilance-related events, disease burden and overall efficiency of care in European countries, 1990-2021
Provisionally accepted
- Xi'an Jiaotong University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: This study aimed to evaluate and compare the disease burden of pharmacovigilance-related events in European countries, to identify the factors related to pharmacovigilance-related inputs in various countries, and to analyze and compare the comprehensive benefits of pharmacovigilance-related events in various countries.Methods: Using the Global Burden of Disease Study 2021 database, we combined information on adverse effects of medical treatment and drug use disorders to identify all pharmacovigilance-related events. We used principal component analysis to synthesize six first-level indicators to compare the burden of disease in each country in each year. We used data envelopment analysis to compare the efficiency of pharmacovigilance in each country. Results: In 2021, the Quality of care index for pharmacovigilance-related events was highest in Northern and Western European countries. Looking at data from 1990 to 2021, the change node of this index in most countries occurred around 2000 to 2010, and the value changed steadily. Countries with relatively low investment in health resources and less experience in supervising adverse drug reactions have higher comprehensive benefits of nursing for pharmacovigilance-related events. Conclusions: The effect of the development of a system for pharmacovigilance has a hysteresis. The disease burden is affected by various factors such as population aging, human resource investment, and medical and health needs, and the policy is highly dominant.
Keywords: Global Burden of Disease study, Pharmacovigilance-related events, Quality of Care Index, data envelopment analysis, European countries
Received: 19 Mar 2025; Accepted: 05 Jun 2025.
Copyright: © 2025 Yin, Lin, Liu, Zhu, Liu, Shen, Li and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bianling Feng, Xi'an Jiaotong University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.